Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (593)	3/30/2006 2:14:14 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 625

From Iceberg, results of cnto's anti il-12/23 Mab in psoriasis. Message 22310239 From CAT's 20-F: ABT-874 is a fully human anti-IL12 monoclonal antibody, isolated and optimized by CAT in collaboration with Abbott, and licensed to Abbott. Abbott is developing ABT-874 as a potential treatment for Crohn’s disease, psoriasis and multiple sclerosis. A Phase II clinical trial continues in multiple sclerosis. In January 2006, Abbott stated that it is “encouraged by the early data for the class of molecule in both psoriasis and Crohn’s disease.” Also in January 2006, Abbott stated that “anticipates publishing data from a Phase II study in multiple sclerosis later in the year.”